RE:RE:RE:New Press Release - Theratechnologies Announces Update on its Preclinical Oncology Research ProgramSo 50M to contribute to the scientific discourse and understandings... 1.5M charges and Well positioned to leverage..... not even funny... thsi ddiot wasted my whole retirement on understandings... FU.
“I am very proud of our exceptional research team, whose work has contributed greatly to the scientific discourse and understanding of advanced cancers,” said Paul Lvesque, President and CEO at Theratechnologies. “Our investment in the SORT1+ Technology™ platform over the past five years has generated important evidence on multiple peptide-drug conjugates with different payloads. Now that we have significantly advanced our preclinical program, we are well-positioned to leverage this wealth of data and insights to attract an oncology R&D partner.”